Milestones

Results from Preclinical Studies:

LGM2605 significantly reduced disease progression in non-human primate asthma models

LGM2605 demonstrated safety in multiple rodent toxicology studies

LGM2605 PK/PD data in non-human primates shows good oral bioavailability

LGM2605 shown to rehabilitate donor lungs to be used in transplant

FDA meeting held 2018 to define development under device guidelines

Robust Intellectual Property:

LignaMed holds exclusive licenses to the patents for LGM2605 from The Trustees of the University Of Pennsylvania and The Scripps Institute

Funding Awarded:

Awarded $5.2 million dollar contract from National Institutes of Health to develop LGM2605 as a medical countermeasure agent to treat radiation lung damage from nuclear accident or attack.

Awarded $278,000 phase I STTR grant award from National Institutes of Health to develop LGM2605 as a treatment for asthma.

Awarded $125,000 phase I SBIR grant award from NASA to develop LGM2605 as a mitigator of space radiation–induced vascular damage. This is part of NASA’s space travel to Mars program.

Awarded $755,000 phase II SBIR grant award from NASA to develop LGM2605 as a mitigator of space radiation–induced vascular damage. This is part of NASA’s space travel to Mars program.

Awarded $300,000 phase I STTR grant award from National Institutes of Health to develop LGM2605 for organ preservation.

Awarded $2.3 million dollar fast track phase I /phase II grant award from National Institutes of Health to develop LGM2605 as a device to rehabilitate donor lungs.

Awarded $3 million NIH/NIAID Phase II STTR grant award for Asthma